methyl 3-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)benzoate | 1093938-36-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)benzoate
• 英文别名: etripamil；methyl 3-[2-[[4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-methylamino]ethyl]benzoate
• CAS: 1093938-36-3
• 化学式: C₂₇H₃₆N₂O₄
• 分子量: 452.594
• InChiKey: VAZNEHLGJGSQEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  33
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  71.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-bromo-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile 、 methyl 3-(2-(methylamino)ethyl)benzoate 以produced 3o的产率得到methyl 3-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)benzoate
  参考文献：
  名称：

  SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

  摘要：

  本发明涉及使用药学有效量的短效钙通道阻滞剂化合物治疗缺血性心脏病、心脏心律失常、急诊室高血压危机、手术前、手术中或手术后高血压、再灌注后无再流现象以及与骨骼肌血流减少相关的疾病。该发明还涉及用于这些方法的制剂和工具包。

  公开号：

  US20160074354A1

文献信息

• [EN] HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF<br/>[FR] SELS TRÈS HYDROSOLUBLES D'UN INHIBITEUR DES CANAUX CALCIQUES À BASE DE PHÉNYLALKYLAMINE À ACTION COURTE ET LEURS UTILISATIONS
  申请人：MILESTONE PHARMACEUTICALS INC

  公开号：WO2016165014A1

  公开（公告）日：2016-10-20

  The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

  本发明包括一种令人惊讶的苯基烷基胺化合物的水溶性盐，这些盐是L型钙通道的有效拮抗剂。包括本发明盐的水溶液被配制用于鼻腔给药，并为稳定型心绞痛、偏头痛和心律失常（如阵发性上室性心动过速）的治疗提供了一种新颖的治疗平台。
• Short acting phenylalkylamine calcium channel blockers and uses thereof
  申请人：Milestone Pharmaceuticals Inc.

  公开号：US09227918B2

  公开（公告）日：2016-01-05

  The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

  本发明涉及使用药理有效量的短效钙通道阻滞剂化合物来治疗缺血性心脏病、心脏心律失常、急诊室高血压危机、手术前、期间或后的高血压、再灌注后的无反流现象以及与骨骼肌血流减少相关的疾病。本发明还涉及用于上述方法的制剂的制备以及用于该方法的工具包。
• Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
  申请人：Milestone Pharmaceuticals Inc.

  公开号：US10117848B2

  公开（公告）日：2018-11-06

  The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

  本发明包括令人惊讶的苯烷基胺化合物水溶性盐，它们是 L 型钙通道的强效拮抗剂。包括本发明盐类的水溶液经配制后可用于鼻腔给药，为治疗稳定型心绞痛、偏头痛和心律失常（如阵发性室上性心动过速）提供了一种新型治疗平台。
• HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF
  申请人：Milestone Pharmaceuticals Inc.

  公开号：EP3283067A1

  公开（公告）日：2018-02-21
• US9227918B2
  申请人：——

  公开号：US9227918B2

  公开（公告）日：2016-01-05